Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.55 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.55 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.55 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891106 | 0.93 | HDAC1 (0.86) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1889670 | 0.90 | HDAC1 (0.81) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1887587 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1884950 | 0.88 | HDAC1 (0.78) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL6509196 | 0.88 | HDAC1 (0.78) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1892313 | 0.83 | HDAC1 (0.71) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1888521 | 0.82 | HDAC1 (1.00) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1883718 | 0.81 | HDAC1 (0.69) | HDAC1HDAC3HDAC4HDAC7HDAC2 | |
| SCHEMBL1886482 | 0.81 | HDAC1 (1.00) | HDAC1 | |
| SCHEMBL6510493 | 0.80 | HDAC1 (0.67) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | claimed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | claimed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | claimed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| US-7935724-B2 | Thiophene and benzothiophene hydroxamic acid derivatives | MERCK HDAC RESEARCH, LLC (US) | 2011-05-03 | — | — | US | disclosed |
| EP-1677731-A4 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | MERCK HDAC RESEARCH, LLC | 2007-09-13 | — | — | US | disclosed |
| EP-1677731-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Aton Pharma, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005066151-A2 | HISTONE DEACETYLASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-21 | — | — | WO | disclosed |
| US-20050137234-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2005-06-23 | — | — | US | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| WO-2005034880-A2 | THIOPHENE AND BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | ATON PHARMA, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213392-A1 | Thiophene and Benzothiophene Hydroxamic Acid Derivatives | BRDT, TXN, TXNRD2 | HDAC1 9/4885HDAC3 27/4885HDAC4 17/4885 |
| US-20050137234-A1 | Histone deacetylase inhibitors | HDAC1, HDAC5, HDAC11 | HDAC1 1/4885HDAC3 4/4885HDAC4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.